Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Chung V, Alistar A, Becerra C, Kasi A, Borazanci E, Jameson GS, Roe DJ, Wertheim BC, Cridebring D, Truitt M, Downes M, Barrett MT, Korn R, Lee K, Han H, Evans R, Von Hoff DD. Pembrolizumab ? paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025 Jan 17; 30(1).
-
Link JM, Eng JR, Pelz C, MacPherson-Hawthorne K, Worth PJ, Sivagnanam S, Keith DJ, Owen S, Langer EM, Grossblatt-Wait A, Salgado-Garza G, Creason AL, Protzek S, Egger J, Holly H, Heskett MB, Chin K, Kirchberger N, Betre K, Bucher E, Kilburn D, Hu Z, Munks MW, English IA, Tsuda M, Goecks J, Demir E, Adey AC, Kardosh A, Lopez CD, Sheppard BC, Guimaraes A, Brinkerhoff B, Morgan TK, Mills GB, Coussens LM, Brody JR, Sears RC. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Nat Cancer. 2025 Jan; 6(1):123-144.
-
Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont CF, Senesac JH, Bayle JH, Scripture CD, Chatwal MS, Bilen MA, Stadler WM, Becerra CR. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 12 30; 15(1):10743.
-
Li Y, Lam SSK, Gao Y, Shore E, Anderson DW, Hode T, Martin RC. Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma. Ann Surg Oncol. 2025 Apr; 32(4):2786-2798.
-
Chao T, Wang ZX, Bowne WB, Yudkoff CJ, Torjani A, Swaminathan V, Kavanagh TR, Roadarmel A, Sholevar CJ, Cannaday S, Krampitz G, Zhan T, Gorgov E, Nevler A, Lavu H, Yeo CJ, Peiper SC, Jiang W. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Arch Pathol Lab Med. 2024 Dec 01; 148(12):1299-1309.
-
Finan JM, Di Niro R, Park SY, Jeong KJ, Hedberg MD, Smith A, McCarthy GA, Haber AO, Muschler J, Sears RC, Mills GB, Gmeiner WH, Brody JR. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Lopez CD, Kardosh A, Chen EY, Pegna G, Guimaraes A, Foster B, Brinkerhoff B, Goodyear SM, Lim JY, Taber E, Rajagopalan B, Edmerson E, Vo J, Nelson K, Jackson A, Gingerich T, Fahlman A, Lessenich C, Fennell F, Ventura D, Roy P, Keith D, Sheppard B, Brody JR, Mills GB, Ronai ZA, Sears RC. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024; 20(37):2915-2925.
-
Zarei M, Hajihassani O, Hue JJ, Loftus AW, Graor HJ, Nakazzi F, Naji P, Boutros CS, Uppin V, Vaziri-Gohar A, Shalaby AS, Asara JM, Rothermel LD, Brody JR, Winter JM. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):3072-3085.
-
Brody JR, Klein AP. The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):2941-2943.
-
Lawrence YR, Miszczyk M, Dawson LA, Diaz Pardo DA, Aguiar A, Limon D, Pfeffer RM, Buckstein M, Barry AS, Meron T, Dicker AP, Wydmanski J, Zimmermann C, Margalit O, Hausner D, Morag O, Golan T, Jacobson G, Dubinski S, Stanescu T, Fluss R, Freedman LS, Ben-Ayun M, Symon Z. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024 Aug; 25(8):1070-1079.